Cardizem Cd

Angina Pectoris, Variant, Atrial Fibrillation, Proteinuria + 11 more

Treatment

6 FDA approvals

20 Active Studies for Cardizem Cd

What is Cardizem Cd

Diltiazem

The Generic name of this drug

Treatment Summary

Diltiazem is a medication used to treat high blood pressure and abnormal heart rhythms. It works by relaxing the blood vessels and decreasing the heart rate. It is usually prescribed in extended-release oral or intravenous forms, and is marketed under different brand names such as Cardizem and Tiazac. It is also sometimes used to treat anal fissures, migraines, pulmonary hypertension, and leg cramps. Diltiazem was approved by the FDA in 1982.

Cardizem

is the brand name

image of different drug pills on a surface

Cardizem Cd Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cardizem

Diltiazem

1982

656

Approved as Treatment by the FDA

Diltiazem, commonly known as Cardizem, is approved by the FDA for 6 uses which include Coronary Vasospasm and Coronary Artery Vasospasm .

Coronary Vasospasm

Helps manage Coronary Artery Vasospasm

Coronary Artery Vasospasm

Helps manage Coronary Artery Vasospasm

Anginal Pain

Helps manage Anginal Pain

Hypertensive disease

Helps manage High Blood Pressure (Hypertension)

Angina, Stable

Helps manage Chronic Stable Angina Pectoris

Angina Pectoris

Helps manage Anginal Pain

Effectiveness

How Cardizem Cd Affects Patients

Diltiazem helps to reduce blood pressure by relaxing the muscles in blood vessels and slowing down the heart rate. It is mainly used to treat hypertension (high blood pressure), but can also be used to treat angina (chest pain). In studies, those taking diltiazem had a lower diastolic blood pressure compared to those taking a placebo, with the greatest decrease seen in those taking the highest dose. This drug may also help to protect against stroke in those with hypertension. Additionally, patients with chronic stable angina taking diltiazem at night have seen an increase in their exercise tolerance.

How Cardizem Cd works in the body

Diltiazem works by blocking the influx of calcium ions into the muscles when they are excited. This stops cells from contracting and reduces the amount of calcium in the cell. This leads to increased relaxation of the heart and blood vessels, which lowers blood pressure and allows more oxygen to be delivered to the heart. It also reduces heart rate and total peripheral resistance, meaning that less energy is needed to pump blood. This helps to improve exercise tolerance in those with chronic stable angina.

When to interrupt dosage

The proposed dose of Cardizem Cd is contingent upon the diagnosed affliction, including prevention of migraine headaches, Fissure;Anal and Anginal Pain. The amount of dosage is dependent on the delivery method outlined in the table below.

Condition

Dosage

Administration

Angina Pectoris

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Atrial Fibrillation

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Coronary Vasospasm

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Angina Pectoris, Variant

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Proteinuria

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Hypertensive disease

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Angina, Stable

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Tachycardia, Supraventricular

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Cardiomyopathy, Dilated

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Migraine Disorders

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Diabetic Neuropathy

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Pulmonary Hypertension

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Fissure in Ano

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Muscle Cramp

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Warnings

Cardizem Cd Contraindications

Condition

Risk Level

Notes

Heart Attack

Do Not Combine

accessory bypass tract

Do Not Combine

accessory bypass tract

Do Not Combine

Bradycardia

Do Not Combine

Ventricular Tachycardia

Do Not Combine

Bradycardia

Do Not Combine

Atrioventricular Block

Do Not Combine

Pulmonary Congestion

Do Not Combine

Shock, Cardiogenic

Do Not Combine

Hypotension

Do Not Combine

There are 20 known major drug interactions with Cardizem Cd.

Common Cardizem Cd Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Diltiazem.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Diltiazem.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Diltiazem.

Alfentanil

Major

The metabolism of Alfentanil can be decreased when combined with Diltiazem.

Amifostine

Major

Diltiazem may increase the hypotensive activities of Amifostine.

Cardizem Cd Toxicity & Overdose Risk

Diltiazem is toxic when taken in large doses, with a lethal dose of 415-740 mg/kg for mice, 560-810 mg/kg for rats, and 360 mg/kg for monkeys. Overdoses of less than 1 gram to 18 grams have been reported and may cause slow heart rate, low blood pressure, abnormal heart rhythm, or heart failure. Treatment for overdose may include supportive care, vomiting, activated charcoal, and medications like atropine, isoproterenol, dopamine, or dobutamine. If taken in smaller doses, diltiazem has not been linked to cancer, mutations,

image of a doctor in a lab doing drug, clinical research

Cardizem Cd Novel Uses: Which Conditions Have a Clinical Trial Featuring Cardizem Cd?

228 active trials are presently investigating the capacity of Cardizem CD to provide relief from Atrial Fibrillation, Coronary Artery Spasm and Paroxysmal Supraventricular Tachycardia (PSVT).

Condition

Clinical Trials

Trial Phases

Atrial Fibrillation

90 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1

Diabetic Neuropathy

6 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Pulmonary Hypertension

33 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1

Tachycardia, Supraventricular

2 Actively Recruiting

Phase 3, Phase 2

Angina, Stable

0 Actively Recruiting

Angina Pectoris, Variant

0 Actively Recruiting

Angina Pectoris

2 Actively Recruiting

Not Applicable, Phase 4

Cardiomyopathy, Dilated

1 Actively Recruiting

Not Applicable

Proteinuria

5 Actively Recruiting

Phase 2, Phase 3, Phase 4, Phase 1

Muscle Cramp

0 Actively Recruiting

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Coronary Vasospasm

0 Actively Recruiting

Migraine Disorders

1 Actively Recruiting

Phase 3

Fissure in Ano

0 Actively Recruiting

Cardizem Cd Reviews: What are patients saying about Cardizem Cd?

5

Patient Review

2/17/2012

Cardizem Cd for Ventricular Rate Control in Atrial Fibrillation

I unfortunately saw negative results from this treatment. Both my blood pressure and heart rate increased, which led me to have to go to the doctor.

4

Patient Review

1/13/2012

Cardizem Cd for Ventricular Rate Control in Atrial Fibrillation

4

Patient Review

1/23/2013

Cardizem Cd for Ventricular Rate Control in Atrial Fibrillation

I have been struggling with feet and ankle swelling as well as fatigue.

3.7

Patient Review

9/2/2012

Cardizem Cd for High Blood Pressure

This medication has been successful in lowering my blood pressure and I have not had any more episodes of racing heart. However, the swelling of my feet is now severe and very uncomfortable. This side effect has really changed my life for the worse and I am worried about it.

3.7

Patient Review

4/12/2013

Cardizem Cd for Ventricular Rate Control in Atrial Fibrillation

The medication did a good job of controlling the rate, but I developed severe swelling and itching in my feet, throat, and lips on day four. I also had difficulty breathing. So, I stopped taking the medication.

3.3

Patient Review

3/13/2013

Cardizem Cd for Ventricular Rate Control in Atrial Fibrillation

I was on 120 mg for 6 weeks and doing great, but then the doctor increased my dosage to 240mg. Now I am experiencing unbearable constipation and will be calling the doctor tomorrow to ask for a change.

3

Patient Review

1/1/2014

Cardizem Cd for High Blood Pressure

Cardizem was great at first, but now I'm feeling really lousy. Dizzy, nauseated, exhausted, and my urine is a weird green color. Not sure if I can continue on this medication.

3

Patient Review

5/9/2012

Cardizem Cd for Ventricular Rate Control in Atrial Fibrillation

This has helped with my SVT, but my blood pressure is now worse.

3

Patient Review

6/11/2012

Cardizem Cd for High Blood Pressure

I have fast heartbeat and high blood pressure, for which I was originally prescribed a beta blocker. However, I was switched to this drug instead and frankly, I can't tell the difference.

2.7

Patient Review

1/18/2014

Cardizem Cd for Ventricular Rate Control in Atrial Fibrillation

Recently, my doctor prescribed this medication for A-Fib. I have been feeling incredibly fatigued and also have had sever stomach pain and sometimes lack of control over bowel movements--both of which are new issues since taking the medication. Additionally, I've been short of breath. I'm going to contact my doctor early next week, but as of now, I am not a fan of this treatment.

2.3

Patient Review

2/9/2012

Cardizem Cd for High Blood Pressure

I saw a rise in my blood pressure after taking this medication for just one week. Additionally, it caused an elevation in my heart rate which made it difficult to sleep. My resting heart rate was in the mid-80s.

2.3

Patient Review

2/7/2012

Cardizem Cd for Diastolic Heart Failure

I was prescribed too high of a dose by my second doctor- 240mg. My first doctor only had me on 120 mg and I didn't have any issues with swelling. Now, my ankles and feet are swollen and I also have Atrial Fibillation.

2

Patient Review

2/17/2014

Cardizem Cd for Ventricular Rate Control in Atrial Fibrillation

I'm undecided on this treatment. I think it lowers blood pressure too much and I've been having burning sensations in my muscles.

1.7

Patient Review

12/2/2012

Cardizem Cd for High Blood Pressure

I started out taking two pills per day, 30 mg each. I began experiencing palpitations, which have since stopped. However, I constantly felt dizzy and lightheaded. I made three trips to the ER before they doubled my medication dosage. Now I think I'm overmedicated; whenever I cut back to just one pill, I feel incredibly dizzy for a few days straight.

1

Patient Review

7/18/2013

Cardizem Cd for High Blood Pressure

I had a terrible allergic reaction to this medication. I developed a red, itchy rash all over my body within one week of taking the drug. The rash lasted for one week, even while taking 50mg of Benadryl 4 times per day.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cardizem cd

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Cardizem CD once daily?

"-Cardizem CD or equivalent (Cartia XT) generic extended-release capsules are to be taken once a day, with or without meals. -Cardizem LA extended-release tablets are to be taken once a day as well, either in the morning or evening, with or without meals."

Answered by AI

What are the side effects of diltiazem CD?

"If you experience any of the following side effects, stop using the cream or ointment and seek medical advice:

swollen hands, ankles or feet, headaches, feeling dizzy and lightheaded, feeling tired, weak and generally unwell, feeling hot (flushing) and redness of the skin, itching or burning on the skin where you use the cream or ointment, stomach pain, indigestion and constipation."

Answered by AI

What does the CD stand for in Cardizem?

"Cardizem and Cardizem CD are both medications that contain the active ingredient diltiazem hydrochloride. The difference between the two is that Cardizem CD is designed to release the active ingredient slowly so that it works over the course of 24 hours and can be taken once a day. The acronym "CD" stands for "controlled delivery.""

Answered by AI

Is diltiazem ER and CD the same?

"DILTIAZEM/Tiazac (dil TYE a zem) is a medication used to treat high blood pressure and prevent chest pain (angina). It works by relaxing the blood vessels, which decreases the workload of the heart. It is classified as a calcium channel blocker."

Answered by AI

Clinical Trials for Cardizem Cd

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Northwestern University in Chicago, United States.

Exercise Program for Atrial Fibrillation and Heart Failure

60 - 99
All Sexes
Chicago, IL

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are very common conditions that often occur together and result in worsening symptoms and reduced quality of life (QoL). Limitations being able to participate in activities of daily living is a primary complaint for AF-HFpEF patients, yet effective strategies to address this issue remain limited. While exercise interventions targeting aerobic training (AT) are recommended for patients with AF and HFpEF, unique challenges exist in this patient population who tend to be older. Specifically, many older patients with AF and HFpEF have muscle weakness, sarcopenia and frailty, that can make aerobic-focused exercise difficult and less tolerable. This study proposes that starting with progressive resistance training (PRT) before aerobic exercise may overcome these issues by improving muscle strength, making AT more manageable, and leading to better health outcomes. The goal of this study is to assess whether a sequential exercise program, named 'PREACTIVE' improves how people feel, decrease the amount of symptoms, and their ability to participate in exercise and activities. This study will specifically test a sequenced exercise approach of resistance training followed by aerobic exercise to improve symptoms, and quality of life in AF-HFpEF.

Waitlist Available
Has No Placebo

Northwestern University

Deepika Laddu, PhD

Image of the FSU TMH Family Practice Residency Program in Tallahassee, United States.

Cannabidiol for Diabetic Neuropathy

40 - 70
All Sexes
Tallahassee, FL

The "Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot study (CBD-DPN1)" is a double-blinded, placebo-controlled, crossover pilot study evaluating the efficacy of Cannabidiol (CBD) and full-spectrum CBD (fsCBD) tinctures in treating Diabetic Peripheral Neuropathy (DPN)-associated pain. DPN is a common, highly distressing complication of diabetes, characterized by chronic pain and loss of sensory function, for which currently available treatments primarily offer only symptomatic relief. CBD and fsCBD are being investigated for their potential neuroprotective and analgesic effects by regulating inflammation and oxidative stress. The study aims to recruit 12 to 20 adult participants who have mild to moderate DPN. Subjects will receive either an active treatment (CBD isolate or fsCBD in MCT oil, dosed at 50 mg twice daily for a total of 100 mg daily) or a placebo during two sequential 6-week phases. The overall objective of this pilot phase is primarily methodological: to test and refine the clinical protocol, assess patient compliance and acceptability of the CBD formulations, and generate sufficient data to calculate the necessary sample size for a larger, definitive study. Efficacy will be measured using objective and subjective metrics, including DPN severity (DN4 Assessment Tool and DPNCheck™ for nerve conduction velocity) and pain level (PainDetect Questionnaire). Secondary outcomes include evaluating mood (HADS), sleep quality (MOS Sleep Scale), and quality of life (EQ-5D-5L).

Phase 1 & 2
Waitlist Available

the FSU TMH Family Practice Residency Program

Have you considered Cardizem Cd clinical trials?

We made a collection of clinical trials featuring Cardizem Cd, we think they might fit your search criteria.
Go to Trials
Image of Grand Island Pain Relief Center in Grand Island, United States.

BurstDR Spinal Cord Stimulation for Diabetic Neuropathy

18+
All Sexes
Grand Island, NE

This prospective, single-arm clinical study evaluates the therapeutic efficacy and feasibility of BurstDR spinal cord stimulation (SCS) using Abbott's Proclaim XR and Eterna systems in patients with painful diabetic neuropathy (PDN). Adults with confirmed PDN will undergo a one-week temporary SCS trial, and those achieving meaningful improvement (≥50% reduction in average pain on the Visual Analog Scale) will proceed to permanent implantation. Outcomes will be assessed at baseline, end of trial, and at 1-, 3-, and 6-month follow-up visits using validated instruments including VAS, DN4, DQoL, PSQ-3, the Patient Global Impression of Change, and the Clinician Global Impression of Change. All procedures follow standard clinical practice for SCS therapy. The study aims to characterize real-world effectiveness, patient-reported outcomes, feasibility of implementation, and device-related safety in a rural PDN population.

Waitlist Available
Has No Placebo

Grand Island Pain Relief Center

TriCity Research Center

Image of Inova Alexandria Hospital in Alexandria, United States.

Heparin Dosing for Blood Clots and Heart Conditions

18+
All Sexes
Alexandria, VA

The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.

Phase 4
Waitlist Available

Inova Alexandria Hospital

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Cardizem Cd clinical trials?

We made a collection of clinical trials featuring Cardizem Cd, we think they might fit your search criteria.
Go to Trials
Image of UPMC Presybeterian in Pittsburgh, United States.

Telaglenastat for Pulmonary Hypertension

18 - 75
All Sexes
Pittsburgh, PA

The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH). PH is a progressive condition that affects the arteries in the lungs, specifically the pulmonary arteries, which carry blood from the right side of the heart to the lungs. Telaglenastat is not currently approved by the Food and Drug Administration for the treatment of PH. However, the study investigators believe that Telaglenastat may help lower blood pressure in the lungs and improve both heart and lung function. It is important to note that the drug will not be available to participants once the study concludes.

Phase 1 & 2
Waitlist Available

UPMC Presybeterian

Michael Risbano, MD

Have you considered Cardizem Cd clinical trials?

We made a collection of clinical trials featuring Cardizem Cd, we think they might fit your search criteria.
Go to Trials